Evidence map›Paper›PMID 29777119›Full record

ArticleScientific reports2018

Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.

Ilaria Sauzullo, Rossana Scrivo, Paola Sessa, Fabio Mengoni, Vincenzo Vullo, Guido Valesini, Claudio Maria Mastroianni

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Specific immune response toFrontiers in immunology · 2024
    Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ilaria SauzulloDepartment of Public Health and Infectious Diseases, 'Sapienza' University, Rome, Italy. ilariasauzullo@libero.it.ORCID 0000-0002-0060-0749
Rossana ScrivoDepartment of Internal Medicine and Medical Specialties, Rheumatology Unit, 'Sapienza' University, Rome, Italy.
Paola SessaDepartment of Internal Medicine and Medical Specialties, Rheumatology Unit, 'Sapienza' University, Rome, Italy.
Fabio MengoniDepartment of Public Health and Infectious Diseases, 'Sapienza' University, Rome, Italy.
Vincenzo VulloDepartment of Public Health and Infectious Diseases, 'Sapienza' University, Rome, Italy.
Guido ValesiniDepartment of Internal Medicine and Medical Specialties, Rheumatology Unit, 'Sapienza' University, Rome, Italy.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, 'Sapienza' University, Rome, Italy.ORCID 0000-0002-1286-467X
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to clarify the effect of long-term anti-TNF therapy on T cell function in patients with rheumatologic immune-mediated inflammatory diseases (IMID). The production of IFNγ by T cells was evaluated at baseline and after 1, 2, 4, and 8 years of anti-TNF agents by means of a QuantiFERON-TB Gold In-Tube assay. The T cell proliferation and surface co-expression of CD25/CD134 in response to phytohaemagglutinin together with the in vitro impact of anti-TNF therapy on the functional capacity of T cells were evaluated after 8 years from the onset of the biological treatment. Age-matched healthy donors were enrolled as controls. The quantitative mitogen-induced IFNγ responses significantly increased with respect to baseline at each time point, apart from the determination after 4 years. We found an increased expression of CD25/CD134 in CD4

Indexed as

AdalimumabAdultAgedArthritis, PsoriaticCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationChronic DiseaseEtanerceptFemaleHumansInterferon-gammaInterleukin-2 Receptor alpha SubunitLongitudinal StudiesMaleMiddle AgedAdalimumabEtanerceptInterferon-gammaInterleukin-2 Receptor alpha SubunitMitogensReceptors, OX40Tumor Necrosis Factor-alpha

Identifiers

PMID29777119
PMCPMC5959893
OpenAlexW2807073140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.